Show simple item record

AuthorVranic, Semir
AuthorGatalica, Zoran
Available date2023-01-22T09:53:42Z
Publication Date2022
Publication NameBosnian Journal of Basic Medical Sciences
ResourceScopus
URIhttp://dx.doi.org/10.17305/bjbms.2021.6100
URIhttp://hdl.handle.net/10576/38677
AbstractAntibody-drug conjugates represent a new class of highly potent antineoplastic drugs built by attaching a small molecule of an anticancer drug (payload) or another therapeutic agent to an antibody recognizing an epitope on the targeted cells. Trophoblast cell-surface antigen-2 (Trop-2) was originally described in trophoblasts and fetal tissues, but subsequently its overexpression has been demonstrated in various solid malignan-cies. Sacituzumab govitecan (SG), a conjugate of anti-Trop-2 antibody and SN-38 payload (an active metabolite of irinotecan), is the first in the class that has been clinically validated and approved by the Food and Drug Administration for the treatment of metastatic triple-negative breast (2020) and urothelial carcinomas (2021). In the current review, we summarize and critically appraise the most recent advances with regard to SG, emphasizing the predictive biomarker analysis.
Languageen
PublisherAssociation of Basic Medical Sciences of FBIH
SubjectAntibody-drug conjugates
Breast cancer
Predictive biomarkers
Sacituzumab govitecan
Trophoblast cell-surface antigen-2
Urothelial cancer
TitleTrop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
TypeArticle
Pagination14-21
Issue Number1
Volume Number22
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record